Search results for "BODIES"

showing 10 items of 2217 documents

Cytokeratins in the Histological Diagnosis of Malignant Tumors

1994

Cytokeratins, which comprise a multigene family of 20 related polypeptides (CKs 1–20), are constituents of the intermediate filaments of epithelial cells, in which they are expressed in various combinations depending on the epithelial type and the degree of differentiation. Of these, CK 19 (400 amino acids; 44.1 kilodaltons) is an example of a widely distributed CK, being expressed in various epithelia, including many simple epithelia. In contrast, the recently identified CK 20 (424 amino acids; 48.6 kilodaltons) is essentially confined to gastrointestinal epithelia, the urothelium and Merkel cells. The differential expression of individual CKs in various types of carcinomas makes them use…

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyCellular differentiationClinical BiochemistryIntermediate FilamentsGene ExpressionBiologyEpitheliumPathology and Forensic Medicine03 medical and health sciencesCytokeratin0302 clinical medicineNeoplasmsKeratinBiomarkers TumorCarcinomamedicineHumansUrotheliumIntermediate filamentchemistry.chemical_classificationAntibodies MonoclonalCell DifferentiationEpithelial Cellsmedicine.disease030104 developmental biologymedicine.anatomical_structureOncologychemistryTumor progression030220 oncology & carcinogenesisKeratinsMerkel cellThe International Journal of Biological Markers
researchProduct

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody

2020

The MET oncogene encodes a tyrosine kinase receptor involved in the control of a complex network of biological responses that include protection from apoptosis and stimulation of cell growth during embryogenesis, tissue regeneration, and cancer progression. We previously developed an antagonist antibody (DN30) inducing the physical removal of the receptor from the cell surface and resulting in suppression of the biological responses to MET. In its bivalent form, the antibody displayed a residual agonist activity, due to dimerization of the lingering receptors, and partial activation of the downstream signaling cascade. The balance between the two opposing activities is variable in different…

0301 basic medicineCancer ResearchProgrammed cell deathlcsh:RC254-282ArticleReceptor tyrosine kinase03 medical and health sciences0302 clinical medicineMET oncogenemedicineantibodiesAntibodies; Apoptosis; MET oncogene; MET targeted therapyReceptorbiologyCell growthChemistryapoptosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmet targeted therapyCell biology030104 developmental biologyOncology<i>met</i> oncogeneApoptosis030220 oncology & carcinogenesisCancer cellbiology.proteinHepatocyte growth factorAntibodymedicine.drugCancers
researchProduct

Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology

2020

Background: The therapeutic outcomes and the prognosis of patients with various hematologic malignancies are not always ideal with the current standard of care. Objective: The aim of this study is to analyze the results of the use of monoclonal antibodies, bispecific antibodies and antibody-drug conjugates for the therapy of malignant hemopathies. Methods: A mini-review was achieved using the articles published in Web of Science and PubMed between January 2017 and January 2020 and the new patents were made in this field. Results: Naked monoclonal antibodies have improved the therapeutic results obtained with standard of care, but they also have side effects and the use of some of them can …

0301 basic medicineCancer ResearchReceptor complexAntibody-drug conjugateImmunoconjugatesmedicine.drug_classmedicine.medical_treatmentAntineoplastic AgentsOfatumumabMonoclonal antibodyPatents as Topic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntigenObinutuzumabAntibodies BispecificDrug DiscoveryAnimalsHumansMedicinePharmacology (medical)Clinical Trials as Topicbusiness.industryAntibodies MonoclonalGeneral MedicineImmunotherapy030104 developmental biologyOncologychemistryHematologic Neoplasms030220 oncology & carcinogenesisMonoclonalCancer researchImmunotherapybusinessRecent Patents on Anti-Cancer Drug Discovery
researchProduct

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

2019

Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC. Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic. Results: We performed an up-to-date critical review taking into account the…

0301 basic medicineCancer Researchmedicine.medical_specialtyAvelumabSkin NeoplasmsPrognosimedicine.medical_treatmentPembrolizumabImmune checkpoint inhibitorCochrane LibraryB7-H1 AntigenSettore MED/13 - EndocrinologiaAvelumab03 medical and health sciencesImmune checkpoint inhibitors0302 clinical medicineMerkel cell carcinomaNeuroendocrine tumoursNeuroendocrine tumourmedicineAnimalsHumansSkin NeoplasmIntensive care medicineMerkel cell carcinomabusiness.industryAnimalAntibodies MonoclonalGeneral MedicineImmunotherapymedicine.diseasePrognosisImmune checkpointBlockadeClinical trialCarcinoma Merkel Cell030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyTherapyAvelumab; Immune checkpoint inhibitors; Merkel cell carcinoma; Neuroendocrine tumours; Pembrolizumab; TherapybusinessPembrolizumabmedicine.drugHuman
researchProduct

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities

2021

Simple Summary The growing interest in immunotherapy for the treatment of multiple myeloma demands a deep knowledge of the complex interactions between malignant and immune cells within the bone marrow. Indeed, understanding the cellular and molecular mechanisms underlying this network should represent the basis for the design of novel patient-oriented biological therapeutic approaches. Here, we describe the role of the main immune components of the myeloma niche along disease evolution and their implication in impairing/improving the response to anti-cancer treatments. Additionally, we provided an overview of the potential weakness of this pro-tumor interplay, evidencing novel therapeutic …

0301 basic medicineCancer Researchmedicine.medical_treatmentReview03 medical and health sciences0302 clinical medicineMedicinetumor immunologyElotuzumabMultiple myelomaRC254-282IsatuximabMonoclonal antibodiebusiness.industryDaratumumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseasePomalidomideanti-cancer immune responseThalidomidemultiple myeloma030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyimmunotherapymonoclonal antibodiesbusinessMonoclonal gammopathy of undetermined significancemedicine.drugCancers
researchProduct

Targeted cancer therapy through antibody fragments-decorated nanomedicines.

2017

Active targeting in cancer nanomedicine, for improved delivery of agents and diagnose, has been reviewed as a successful way for facilitating active uptake of theranostic agents by the tumor cells. The application of a targeting moiety in the targeted carrier complexes can play an important role in differentiating between tumor and healthy tissues. The pharmaceutical carriers, as main part of complexes, can be polymeric nanoparticles, micelles, liposomes, nanogels and carbon nanotubes. The antibodies are among the natural ligands with highest affinity and specificity to target pharmaceutical nanoparticle conjugates. However, the limitations, such as size and long circulating half-lives, hin…

0301 basic medicineCancer therapyPharmaceutical ScienceAntibody fragments03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsAntibodies BispecificmedicineMoietyAnimalsHumansImmunoglobulin FragmentsLiposomebiologyChemistryCancermedicine.diseaseMolecular biology030104 developmental biologyNanomedicine030220 oncology & carcinogenesisbiology.proteinCancer researchNanomedicineNanoparticlesAntibodyConjugateJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Genetics and pathophysiology of granulomatosis with polyangiitis (GPA) and its main autoantigen proteinase 3.

2016

Granulomatosis with polyangiitis (GPA) is a severe autoimmune disease and one of the small vessel anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Although its etiology and pathophysiology are still widely unknown, it is accepted that infections, environmental factors, epigenetic modifications, and a genetic predisposition provide the basis for this systemic disorder. GPA typically evolves into two phases: an initial phase characterized by ear, nose and throat (ENT) manifestations, such as chronic sinusitis and otitis, ulceration of the oral cavity and pharynx, as well as pulmonary nodules and a severe generalized phase, defined by the occurrence of rapidly progressive g…

0301 basic medicineCandidate geneMyeloblastinGenome-wide association studyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitismacromolecular substancesBiologyAutoantigensAntibodies Antineutrophil CytoplasmicPTPN2203 medical and health sciencesMice0302 clinical medicinestomatognathic systemProteinase 3medicineGenetic predispositionRapidly progressive glomerulonephritisAnimalsHumansGenetic Predisposition to DiseaseMolecular Biology030203 arthritis & rheumatologyAutoimmune diseaseGranulomatosis with PolyangiitisCell Biologymedicine.disease030104 developmental biologyImmunologyGranulomatosis with polyangiitisGenome-Wide Association StudyMolecular and cellular probes
researchProduct

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

2017

Bidirectional cross talk between members of the human epidermal growth factor family of receptors (HER) and the estrogen receptor (ER) is believed to underlie resistance mechanisms that develop in response to treatment with anti-HER agents and endocrine therapy. We investigated the interaction between HER2, HER3 and the ER in vitro using human embryonic kidney cells transfected with human HER2, HER3, and ERα. We also investigated the additive efficacy of combination regimens consisting of anti-HER3 (lumretuzumab), anti-HER2 (pertuzumab), and endocrine (fulvestrant) therapy in vivo. Our data show that both HER2 and HER3 can directly complex with the ER and can mediate phosphorylation of the …

0301 basic medicineCell signalingReceptor ErbB-3Receptor ErbB-2Cancer TreatmentEstrogen receptorlcsh:MedicineSignal transductionBiochemistryMice0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsBreast TumorsMedicine and Health SciencesReceptorlcsh:Scienceskin and connective tissue diseasesMultidisciplinaryRemission InductionEndocrine TherapySignaling cascadesPrecipitation TechniquesTreatment OutcomeReceptors EstrogenOncology030220 oncology & carcinogenesisMonoclonalCell linesFemalePertuzumabBiological culturesmedicine.drugResearch ArticleAdultCell biologyMAPK signaling cascadesPaclitaxelBreast NeoplasmsAntibodies Monoclonal Humanized03 medical and health sciencesBreast cancerCell Line TumorBreast CancermedicineEndocrine systemAnimalsHumansImmunoprecipitationFulvestrantbusiness.industrylcsh:RHEK 293 cellsCancers and NeoplasmsBiology and Life SciencesEstrogensReceptor Cross-TalkLumretuzumabmedicine.diseaseXenograft Model Antitumor AssaysHormonesResearch and analysis methods030104 developmental biologyCancer researchlcsh:QbusinessPloS one
researchProduct

Cell-Autonomous and Non-cell-autonomous Function of Hox Genes Specify Segmental Neuroblast Identity in the Gnathal Region of the Embryonic CNS in Dro…

2016

During central nervous system (CNS) development neural stem cells (Neuroblasts, NBs) have to acquire an identity appropriate to their location. In thoracic and abdominal segments of Drosophila, the expression pattern of Bithorax-Complex Hox genes is known to specify the segmental identity of NBs prior to their delamination from the neuroectoderm. Compared to the thoracic, ground state segmental units in the head region are derived to different degrees, and the precise mechanism of segmental specification of NBs in this region is still unclear. We identified and characterized a set of serially homologous NB-lineages in the gnathal segments and used one of them (NB6-4 lineage) as a model to i…

0301 basic medicineCentral Nervous SystemCancer ResearchEmbryologyGene ExpressionNervous SystemNeural Stem CellsAnimal CellsMedicine and Health SciencesDrosophila ProteinsHox geneGenetics (clinical)Regulation of gene expressionGeneticsNeuronsMembrane GlycoproteinsDrosophila MelanogasterGene Expression Regulation DevelopmentalAnimal ModelsProtein-Tyrosine KinasesNeural stem cellCell biologyInsectsPhenotypesembryonic structuresDrosophilaDrosophila melanogasterAnatomyCellular Structures and OrganellesCellular TypesResearch Articleanimal structuresArthropodalcsh:QH426-470ImmunoglobulinsBiologyAntennapediaResearch and Analysis Methods03 medical and health sciencesModel OrganismsNeuroblastNuclear BodiesCyclin EGeneticsAnimalsGene RegulationCell LineageMolecular BiologyEcology Evolution Behavior and SystematicsLoss functionCell NucleusHomeodomain ProteinsNeuroectodermEmbryosOrganismsBiology and Life SciencesCell Biologybiology.organism_classificationInvertebrateslcsh:Genetics030104 developmental biologyCellular NeuroscienceDevelopmental BiologyNeurosciencePLoS Genetics
researchProduct

A rare association of chronic lymphocytic leukemia with c-ANCA-positive Wegener’s granulomatosis: a case report

2016

Background Wegener’s granulomatosis is a systemic vasculitis of the small- and medium-sized vessels, produced by the action of ANCA, which involves the respiratory tract, kidneys, and eyes, with a potential for lethal evolution in the first year after diagnosis. Its association with chronic lymphocytic leukemia is rarely described in the literature, and it may be difficult to diagnose and to treat this association. Case presentation We present the case of a 73-year-old Caucasian patient, a rare case in which Wegener’s granulomatosis is associated in a patient with chronic lymphocytic leukemia, who is admitted in the Infectious Disease Department for fever, diplopia, headache, purulent and h…

0301 basic medicineChemosisMalePathologymedicine.medical_specialtyChronic lymphocytic leukemiaMucous membrane of noseCase ReportAntibodies Antineutrophil Cytoplasmic03 medical and health sciences0302 clinical medicineBiopsymedicinec-ANCA positiveHumansAgedmedicine.diagnostic_testbusiness.industryGranulomatosis with PolyangiitisWegener’s granulomatosismedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyOncology030220 oncology & carcinogenesisChronic lymphocytic leukemiaSurgerymedicine.symptomGranulomatosis with polyangiitisVasculitisbusinessScleritisSystemic vasculitisWorld Journal of Surgical Oncology
researchProduct